CONSUN PHARMAC.GR.HD -10 - Asset Resilience Ratio
CONSUN PHARMAC.GR.HD -10 (C1P) has an Asset Resilience Ratio of 41.64% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See C1P net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how CONSUN PHARMAC.GR.HD -10's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see CONSUN PHARMAC.GR.HD -10 (C1P) total assets.
Liquid Assets Composition Over Time
This chart breaks down CONSUN PHARMAC.GR.HD -10's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read C1P total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €2.67 Billion | 41.64% |
| Total Liquid Assets | €2.67 Billion | 41.64% |
Asset Resilience Insights
- Very High Liquidity: CONSUN PHARMAC.GR.HD -10 maintains exceptional liquid asset reserves at 41.64% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
CONSUN PHARMAC.GR.HD -10 Industry Peers by Asset Resilience Ratio
Compare CONSUN PHARMAC.GR.HD -10's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Jiuzhitang Co Ltd
SHE:000989 |
Drug Manufacturers - Specialty & Generic | 7.86% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for CONSUN PHARMAC.GR.HD -10 (2021–2025)
The table below shows the annual Asset Resilience Ratio data for CONSUN PHARMAC.GR.HD -10.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 41.64% | €2.67 Billion ≈ $3.12 Billion |
€6.41 Billion ≈ $7.49 Billion |
+25.27pp |
| 2024-12-31 | 16.37% | €958.00 Million ≈ $1.12 Billion |
€5.85 Billion ≈ $6.84 Billion |
+1.21pp |
| 2023-12-31 | 15.16% | €834.94 Million ≈ $976.13 Million |
€5.51 Billion ≈ $6.44 Billion |
+3.12pp |
| 2022-12-31 | 12.04% | €589.17 Million ≈ $688.80 Million |
€4.89 Billion ≈ $5.72 Billion |
+6.77pp |
| 2021-12-31 | 5.27% | €230.00 Million ≈ $268.89 Million |
€4.36 Billion ≈ $5.10 Billion |
-- |
About CONSUN PHARMAC.GR.HD -10
Consun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. It operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney… Read more